Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-09-02

FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Briviact (brivaracetam) filed by UCB, Inc., authorizing changes to its labeling or indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Briviact (brivaracetam)

Snippet

SUPPL AP for BRIVIACT (BRIVARACETAM)